Clinicopathological and prognostic significance of metastasis-associated in colon cancer-1 (MACC1) overexpression in colorectal cancer: a meta-analysis
Metrics: PDF 2508 views | HTML 1932 views | ?
Yang Zhao1,*, Cong Dai1,*, Meng Wang1, Huafeng Kang1, Shuai Lin1, Pengtao Yang1, Xinghan Liu1, Kang Liu1, Peng Xu1, Yi Zheng1, Shanli Li1 and Zhijun Dai1
1 Department of Oncology, Second Affiliated Hospital of Xi’an Jiaotong University, Xi’an, China
* These authors have contributed equally to this work and share joint first authorship
Zhijun Dai, email:
Keywords: MACC1, colorectal cancer, prognosis, meta-analysis
Received: May 13, 2016 Accepted: July 19, 2016 Published: August 14, 2016
Metastasis-associated in colon cancer-1 (MACC1) has been reported to be overexpressed in diverse human malignancies, and the increasing amount of evidences suggest that its overexpression is associated with the development and progression of many human tumors. However, the prognostic and clinicopathological value of MACC1 in colorectal cancer remains inconclusive. Therefore, we conducted this meta-analysis to investigate the effect of MACC1 overexpression on clinicopathological features and survival outcomes in colorectal cancer. PubMed, CNKI, and Wanfang databases were searched for relevant articles published update to December 2015. Correlation of MACC1 expression level with overall survival (OS), disease-free survival (DFS), and clinicopathological features were analyzed. In this meta-analysis, fifteen studies with a total of 2,161 colorectal cancer patients were included. Our results showed that MACC1 overexpression was significantly associated with poorer OS and DFS. Moreover, MACC1 overexpression was significantly associated with gender, localization, TNM stage, T stage, and N stage. Together, our meta-analysis showed that MACC1 overexpression was significantly associated with poor survival rates, regional invasion and lymph-node metastasis. MACC1 expression level can serve as a novel prognostic factor in colorectal cancer patients.
All site content, except where otherwise noted, is licensed under a Creative Commons Attribution 3.0 License.